BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 21885079)

  • 1. Parainfluenza virus 5-based vaccine vectors expressing vaccinia virus (VACV) antigens provide long-term protection in mice from lethal intranasal VACV challenge.
    Clark KM; Johnson JB; Kock ND; Mizel SB; Parks GD
    Virology; 2011 Oct; 419(2):97-106. PubMed ID: 21885079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential antigen requirements for protection against systemic and intranasal vaccinia virus challenges in mice.
    Kaufman DR; Goudsmit J; Holterman L; Ewald BA; Denholtz M; Devoy C; Giri A; Grandpre LE; Heraud JM; Franchini G; Seaman MS; Havenga MJ; Barouch DH
    J Virol; 2008 Jul; 82(14):6829-37. PubMed ID: 18448519
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protection against lethal vaccinia virus challenge by using an attenuated matrix protein mutant vesicular stomatitis virus vaccine vector expressing poxvirus antigens.
    Braxton CL; Puckett SH; Mizel SB; Lyles DS
    J Virol; 2010 Apr; 84(7):3552-61. PubMed ID: 20089648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Four-gene-combination DNA vaccine protects mice against a lethal vaccinia virus challenge and elicits appropriate antibody responses in nonhuman primates.
    Hooper JW; Custer DM; Thompson E
    Virology; 2003 Feb; 306(1):181-95. PubMed ID: 12620810
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccination of BALB/c mice with Escherichia coli-expressed vaccinia virus proteins A27L, B5R, and D8L protects mice from lethal vaccinia virus challenge.
    Berhanu A; Wilson RL; Kirkwood-Watts DL; King DS; Warren TK; Lund SA; Brown LL; Krupkin AK; Vandermay E; Weimers W; Honeychurch KM; Grosenbach DW; Jones KF; Hruby DE
    J Virol; 2008 Apr; 82(7):3517-29. PubMed ID: 18199639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DNA vaccination with vaccinia virus L1R and A33R genes protects mice against a lethal poxvirus challenge.
    Hooper JW; Custer DM; Schmaljohn CS; Schmaljohn AL
    Virology; 2000 Jan; 266(2):329-39. PubMed ID: 10639319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neutralizing and protective antibodies directed against vaccinia virus envelope antigens.
    Galmiche MC; Goenaga J; Wittek R; Rindisbacher L
    Virology; 1999 Feb; 254(1):71-80. PubMed ID: 9927575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential efficacy of vaccinia virus envelope proteins administered by DNA immunisation in protection of BALB/c mice from a lethal intranasal poxvirus challenge.
    Pulford DJ; Gates A; Bridge SH; Robinson JH; Ulaeto D
    Vaccine; 2004 Sep; 22(25-26):3358-66. PubMed ID: 15308360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Active vaccination with vaccinia virus A33 protects mice against lethal vaccinia and ectromelia viruses but not against cowpoxvirus; elucidation of the specific adaptive immune response.
    Paran N; Lustig S; Zvi A; Erez N; Israely T; Melamed S; Politi B; Ben-Nathan D; Schneider P; Lachmi B; Israeli O; Stein D; Levin R; Olshevsky U
    Virol J; 2013 Jul; 10():229. PubMed ID: 23842430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the vaccinia virus L1 protein to the cell surface enhances production of neutralizing antibodies.
    Golden JW; Josleyn MD; Hooper JW
    Vaccine; 2008 Jun; 26(27-28):3507-15. PubMed ID: 18485547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibodies against the extracellular enveloped virus B5R protein are mainly responsible for the EEV neutralizing capacity of vaccinia immune globulin.
    Bell E; Shamim M; Whitbeck JC; Sfyroera G; Lambris JD; Isaacs SN
    Virology; 2004 Aug; 325(2):425-31. PubMed ID: 15246280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An investigation of the therapeutic value of vaccinia-immune IgG in a mouse pneumonia model.
    Law M; Pütz MM; Smith GL
    J Gen Virol; 2005 Apr; 86(Pt 4):991-1000. PubMed ID: 15784892
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Single-Dose Recombinant Parainfluenza Virus 5-Vectored Vaccine Expressing Respiratory Syncytial Virus (RSV) F or G Protein Protected Cotton Rats and African Green Monkeys from RSV Challenge.
    Wang D; Phan S; DiStefano DJ; Citron MP; Callahan CL; Indrawati L; Dubey SA; Heidecker GJ; Govindarajan D; Liang X; He B; Espeseth AS
    J Virol; 2017 Jun; 91(11):. PubMed ID: 28298602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potent neutralization of vaccinia virus by divergent murine antibodies targeting a common site of vulnerability in L1 protein.
    Kaever T; Meng X; Matho MH; Schlossman A; Li S; Sela-Culang I; Ofran Y; Buller M; Crump RW; Parker S; Frazier A; Crotty S; Zajonc DM; Peters B; Xiang Y
    J Virol; 2014 Oct; 88(19):11339-55. PubMed ID: 25031354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modified Vaccinia Virus Ankara Can Induce Optimal CD8
    Wong YC; Croft S; Smith SA; Lin LCW; Cukalac T; La Gruta NL; Drexler I; Tscharke DC
    J Virol; 2019 Nov; 93(21):. PubMed ID: 31375596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccinia virus H3L envelope protein is a major target of neutralizing antibodies in humans and elicits protection against lethal challenge in mice.
    Davies DH; McCausland MM; Valdez C; Huynh D; Hernandez JE; Mu Y; Hirst S; Villarreal L; Felgner PL; Crotty S
    J Virol; 2005 Sep; 79(18):11724-33. PubMed ID: 16140750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protective immunity to vaccinia virus induced by vaccination with multiple recombinant outer membrane proteins of intracellular and extracellular virions.
    Fogg C; Lustig S; Whitbeck JC; Eisenberg RJ; Cohen GH; Moss B
    J Virol; 2004 Oct; 78(19):10230-7. PubMed ID: 15367588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A recombinant flagellin-poxvirus fusion protein vaccine elicits complement-dependent protection against respiratory challenge with vaccinia virus in mice.
    Delaney KN; Phipps JP; Johnson JB; Mizel SB
    Viral Immunol; 2010 Apr; 23(2):201-10. PubMed ID: 20374000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased attenuation but decreased immunogenicity by deletion of multiple vaccinia virus immunomodulators.
    Sumner RP; Ren H; Ferguson BJ; Smith GL
    Vaccine; 2016 Sep; 34(40):4827-34. PubMed ID: 27544585
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protection of mice against the highly pathogenic VV
    Bissa M; Quaglino E; Zanotto C; Illiano E; Rolih V; Pacchioni S; Cavallo F; De Giuli Morghen C; Radaelli A
    Antiviral Res; 2016 Oct; 134():182-191. PubMed ID: 27637905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.